"We've finally pushed open a door to an entirely new pathway of potential approaches to treat cancer," Walter Klemp, chair and CEO of Moleculin Biotech Inc., said about the initiation of an investigator-led phase I study of STAT3 inhibitor WP-1066 in glioblastoma at MD Anderson Cancer Center. "People have been pounding on this door for a long time, and it was painful getting here, but now it's opened."